Tags

Type your tag names separated by a space and hit enter

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Oncotarget. 2016 May 24; 7(21):30772-80.O

Abstract

AIMS

To evaluate the expression of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) and their clinical and prognostic significance in primary esophageal squamous cell carcinoma (ESCC).

RESULTS

The expression rate of PD-1 and PD-L1 in ESCC was 33.5% (117/349) and 41.4% (222/536), respectively. PD-L1 expression differed significantly by tumor location, grade, lymph node metastases, and disease stage (P < 0.05). Moreover, its expression was associated with the disease free survival (DFS). Patients with positive PD-L1 expression had reduced risk for disease relapse compared to those without PD-L1 expression (Hazard ratio [HR] = 0.75, 95% confidence interval [CI]: 0.56-1.00, P = 0.048). Kaplan-Meier curves showed the similar result, P = 0.047. However, there was no significant correlation between PD-1 expression and clinicopathological factors or outcome in ESCC (P > 0.05).

METHODS

The expression of PD-1 and PD-L1 was assessed by immunohistochemistry on tissue microarrays from 536 primary ESCC who underwent surgery during January 2008 and April 2012 in Zhejiang Cancer Hospital. Chi-square test and Cox proportional hazards regression were employed to analyze the associations between their expressions and clinicopathological variables and survival.

CONCLUSIONS

Our results suggested that PD-L1 could be a favorable indicator of prognosis in ESCC.

Links

Publisher Full Text
ncbi.nlm.nih.gov
oncotarget.com
PMC Free PDF

Authors+Show Affiliations

Chen K
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China. Department of Oncology, The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Cheng G
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China. Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, China.
Zhang F
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
Zhang N
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
Li D
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China. Department of Oncology, The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Jin J
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
Wu J
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
Ying L
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
Mao W
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
Su D
Cancer Research Institute, Zhejiang Cancer Hospital and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.

MeSH

AdultAgedB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellDisease-Free SurvivalEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorProportional Hazards ModelsRetrospective StudiesTissue Array Analysis

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27120796

Citation

Chen, Kaiyan, et al. "Prognostic Significance of Programmed Death-1 and Programmed Death-ligand 1 Expression in Patients With Esophageal Squamous Cell Carcinoma." Oncotarget, vol. 7, no. 21, 2016, pp. 30772-80.
Chen K, Cheng G, Zhang F, et al. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2016;7(21):30772-80.
Chen, K., Cheng, G., Zhang, F., Zhang, N., Li, D., Jin, J., Wu, J., Ying, L., Mao, W., & Su, D. (2016). Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget, 7(21), 30772-80. https://doi.org/10.18632/oncotarget.8956
Chen K, et al. Prognostic Significance of Programmed Death-1 and Programmed Death-ligand 1 Expression in Patients With Esophageal Squamous Cell Carcinoma. Oncotarget. 2016 May 24;7(21):30772-80. PubMed PMID: 27120796.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. AU - Chen,Kaiyan, AU - Cheng,Guoping, AU - Zhang,Fanrong, AU - Zhang,Nan, AU - Li,Dan, AU - Jin,Jiaoyue, AU - Wu,Junzhou, AU - Ying,Lisha, AU - Mao,Weimin, AU - Su,Dan, PY - 2016/02/14/received PY - 2016/04/02/accepted PY - 2016/4/28/entrez PY - 2016/4/28/pubmed PY - 2017/12/30/medline KW - PD-1 KW - PD-L1 KW - esophageal cancer KW - immunochemistry KW - prognosis SP - 30772 EP - 80 JF - Oncotarget JO - Oncotarget VL - 7 IS - 21 N2 - AIMS: To evaluate the expression of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) and their clinical and prognostic significance in primary esophageal squamous cell carcinoma (ESCC). RESULTS: The expression rate of PD-1 and PD-L1 in ESCC was 33.5% (117/349) and 41.4% (222/536), respectively. PD-L1 expression differed significantly by tumor location, grade, lymph node metastases, and disease stage (P < 0.05). Moreover, its expression was associated with the disease free survival (DFS). Patients with positive PD-L1 expression had reduced risk for disease relapse compared to those without PD-L1 expression (Hazard ratio [HR] = 0.75, 95% confidence interval [CI]: 0.56-1.00, P = 0.048). Kaplan-Meier curves showed the similar result, P = 0.047. However, there was no significant correlation between PD-1 expression and clinicopathological factors or outcome in ESCC (P > 0.05). METHODS: The expression of PD-1 and PD-L1 was assessed by immunohistochemistry on tissue microarrays from 536 primary ESCC who underwent surgery during January 2008 and April 2012 in Zhejiang Cancer Hospital. Chi-square test and Cox proportional hazards regression were employed to analyze the associations between their expressions and clinicopathological variables and survival. CONCLUSIONS: Our results suggested that PD-L1 could be a favorable indicator of prognosis in ESCC. SN - 1949-2553 UR - https://www.unboundmedicine.com/medline/citation/27120796/Prognostic_significance_of_programmed_death_1_and_programmed_death_ligand_1_expression_in_patients_with_esophageal_squamous_cell_carcinoma_ L2 - https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.8956 DB - PRIME DP - Unbound Medicine ER -